AN2 Therapeutics, Inc.

NasdaqGS ANTX

AN2 Therapeutics, Inc. Free Cash Flow Yield on January 14, 2025: -167.48%

AN2 Therapeutics, Inc. Free Cash Flow Yield is -167.48% on January 14, 2025, a -1,811.93% change year over year. Free cash flow yield compares the return from free cash flow to the market cap; higher yield suggests attractive investment.

AN2 Therapeutics, Inc. 52-week high Free Cash Flow Yield is -8.50% on February 05, 2024, which is 94.92% above the current Free Cash Flow Yield.
AN2 Therapeutics, Inc. 52-week low Free Cash Flow Yield is -207.91% on August 16, 2024, which is -24.14% below the current Free Cash Flow Yield.
AN2 Therapeutics, Inc. average Free Cash Flow Yield for the last 52 weeks is -114.55%.

Key data

Date	Free Cash Flow Yield	Market Value Added (MVA)	Price to Book Ratio (P/B)	Price to Earnings Ratio (P/E)

NasdaqGS: ANTX

AN2 Therapeutics, Inc.

CEO	Mr. Eric E. Easom
IPO Date	March 25, 2022
Location	United States
Headquarters	1800 El Camino Real
Employees	41
Sector	Health Care
Industries Pharmaceuticals Biotechnology Clinical Trials

Description

AN2 Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for rare, chronic, and serious infectious diseases. It is developing epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial lung disease. The company was incorporated in 2017 and is headquartered in Menlo Park, California.

Key trends

Past 5 years